- Lobbying
- Lobbying by BioCryst Pharmaceuticals, Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
L.F. Payne | United States Congressman |
Mona Mohib | Special Assistant & Associate Dir, Office of Intergovernmental Affairs - White House Director, Intergovernmental Affairs - White House Special Assist: Office of Intergoverment Affairs the White House Assoc Dir, Office of Intergoverment Affairs Intergovernment Affairs -- White House Director, Intergovermental Affairs - Dept of Labor |
Tom Walls | Legislative Assistant, Senator Dale Bumpers Legislative Director, Senator Russ Feingold |
Ronald Platt | n/a |
Ron Platt | n/a |
Frank Donatelli | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q4 Report
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Health & Human Services - Dept of (HHS)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Registration
Issue(s) they said they’d lobby about: Funding for research and development of pharmaceuticals.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate